These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24798484)

  • 1. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
    Hanfstein B; Shlyakhto V; Lauseker M; Hehlmann R; Saussele S; Dietz C; Erben P; Fabarius A; Proetel U; Schnittger S; Krause SW; Schubert J; Einsele H; Hänel M; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Pfirrmann M; Hasford J; Hofmann WK; Hochhaus A; Müller MC;
    Leukemia; 2014 Oct; 28(10):1988-92. PubMed ID: 24798484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.
    Kim DD; Hamad N; Lee HG; Kamel-Reid S; Lipton JH
    Am J Hematol; 2014 Jun; 89(6):626-32. PubMed ID: 24619861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
    Yin XF; Ma QL; Mu QT; Shao L; Wang SS; Meng HT; Xu WL; Wang YG; Chen ZM; Chen FF; Jin J
    Leuk Res; 2014 Oct; 38(10):1191-8. PubMed ID: 25115808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
    Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
    Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
    Press RD; Willis SG; Laudadio J; Mauro MJ; Deininger MW
    Blood; 2009 Sep; 114(13):2598-605. PubMed ID: 19625707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.
    Klamová H; Poláková KM; Mužík J; Ráčil Z; Záčková D; Steinerová K; Karas M; Faber E; Demečková E; Michalovičová-Sninská Z; Voglová J; Demitrovičová L; Mikušková E; Tóthová E; Chudej J; Markuljak I; Cmunt E; Moravcová J; Dvořáková D; Michalová K; Jarošová M; Sťastná MM; Cetkovský P; Dušek L; Koza V; Trněný M; Indrák K
    Cancer Med; 2013 Apr; 2(2):216-25. PubMed ID: 23634289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
    Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
    Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.
    Branford S; Yeung DT; Parker WT; Roberts ND; Purins L; Braley JA; Altamura HK; Yeoman AL; Georgievski J; Jamison BA; Phillis S; Donaldson Z; Leong M; Fletcher L; Seymour JF; Grigg AP; Ross DM; Hughes TP
    Blood; 2014 Jul; 124(4):511-8. PubMed ID: 24859364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
    Lucas CM; Harris RJ; Giannoudis A; Davies A; Knight K; Watmough SJ; Wang L; Clark RE
    Haematologica; 2009 Oct; 94(10):1362-7. PubMed ID: 19713230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
    Branford S; Kim DW; Soverini S; Haque A; Shou Y; Woodman RC; Kantarjian HM; Martinelli G; Radich JP; Saglio G; Hochhaus A; Hughes TP; Müller MC
    J Clin Oncol; 2012 Dec; 30(35):4323-9. PubMed ID: 23109697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
    Martinelli G; Iacobucci I; Rosti G; Pane F; Amabile M; Castagnetti F; Cilloni D; Soverini S; Testoni N; Specchia G; Merante S; Zaccaria A; Frassoni F; Saglio G; Baccarani M
    Ann Oncol; 2006 Mar; 17(3):495-502. PubMed ID: 16403813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
    Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
    Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early monitoring of BCR-ABL transcript levels and cytogenetic in assessing the prognosis of chronic myeloid leukemia].
    Huang Q; Zhang XY; Li Y; Wang XM
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3049-53. PubMed ID: 24417926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
    Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.